Showing results (11-20 of 47) with videos related to
Sort By:
Pageof 5
American Journal of Cancer Research|November 16, 2023
IL25+ macrophages are a key determinant of treatment resistance of IL17RB+ breast cancerYukinori Ozaki, Keiichi Kinowaki, Hidetaka Kawabata, et al.Clinical & Experimental Metastasis|November 13, 2012
CCL2 is critical for immunosuppression to promote cancer metastasisChie Kudo-Saito, Hiromi Shirako, Misa Ohike, et al.Journal for Immunotherapy of Cancer|July 15, 2021
CD11b+CTLA4+ myeloid cells are a key driver of tumor evasion in colorectal cancerHiroshi Imazeki, Yamato Ogiwara, Mami Kawamura, et al.American Journal of Cancer Research|September 13, 2024
Prognostic significance of the FSTL1-DIP2A axis in early-stage tongue cancerChie Kudo-Saito, Satoko Matsumura, Taisuke Mori, et al.Scientific Reports|February 7, 2017
Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric AcidShin Mukai, Yoko Ogawa, Fumihiko Urano, et al.BJC Reports|March 14, 2026
IL10RB expression in cancer cells is associated with evolutionary changes to solidify treatment resistanceChie Kudo-Saito, Hiroki Ozawa, Hiroshi Imazeki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumorsChie Kudo-Saito, Jeffrey Schlom, Kevin Camphausen, et al.Cancer Letters|April 19, 2022
Blocking FSTL1 boosts NK immunity in treatment of osteosarcomaYamato Ogiwara, Makoto Nakagawa, Fumihiko Nakatani, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 10, 2005
Multiple costimulatory modalities enhance CTL avidityJames W Hodge, Mala Chakraborty, Chie Kudo-Saito, et al.Cancer Research|March 12, 2020
IL33 Is a Key Driver of Treatment Resistance of CancerChie Kudo-Saito, Takahiro Miyamoto, Hiroshi Imazeki, et al.Pageof 5